Cytokines in Multiple Myeloma

  • John De Vos
  • Bernard Klein
Chapter
Part of the Current Clinical Oncology book series (CCO)

Abstract

Multiple myeloma (MM) is a neoplasm characterized by the clonal accumulation of malignant plasma cells. Myeloma cells localize in the bone marrow, where their survival is strongly dependent on the normal stromal cells that secrete cytokines and interact with the malignant cells through adhesion molecules. This chapter briefly summarizes the main features of normal plasma cell development. It will then consider recent information on the cytokines that control myeloma cell growth and survival and discuss the pathobiological relevance of these data.

Keywords

Multiple Myeloma Plasma Cell Hepatocyte Growth Factor Myeloma Cell Bone Marrow Stromal Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Liu YJ, de Bouteiller O, Fugier-Vivier I. Mechanisms of selection and differentiation in germinal centers. Curr Opin Immunol 1997; 9:256–262.PubMedCrossRefGoogle Scholar
  2. 2.
    Choe J, Kim HS, Armitage RJ, Choi YS. The functional role of B cell antigen receptor stimulation and IL-4 in the generation of human memory B cells from germinal center B cells. J Immunol 1997; 159:3757–3766.PubMedGoogle Scholar
  3. 3.
    Randall TD, Heath AW, Santos-Argumedo L, Howard MC, Weissman IL, Lund FE. Arrest of B lymphocyte terminal differentiation by CD40 signaling: mechanism for lack of antibody-secreting cells in germinal centers. Immunity 1998; 8:733–742.PubMedCrossRefGoogle Scholar
  4. 4.
    Arpin C, Dechanet J, Van Kooten C, et al. Generation of memory B cells and plasma cells in vitro. Science 1995; 268:720–722.PubMedCrossRefGoogle Scholar
  5. 5.
    Choe J, Choi YS. IL-10 interrupts memory B cell expansion in the germinal center by inducing differentiation into plasma cells. Eur J Immunol 1998; 28:508–515.PubMedCrossRefGoogle Scholar
  6. 6.
    Jacquot S, Kobata T, Iwata S, Morimoto C, Schlossman SF. CD 154/CD40 and CD70/CD27 interactions have different and sequential functions in T cell-dependent B cell responses: enhancement of plasma cell differentiation by CD27 signaling. J Immunol 1997; 159: 2652–2657.PubMedGoogle Scholar
  7. 7.
    Jelinek DF, Lipsky PE. The role of B cell proliferation in the generation of immunoglobulinsecreting cells in man. J Immunol 1983; 130:2597–2604.PubMedGoogle Scholar
  8. 8.
    Vernino L, McAnally LM, Ramberg J, Lipsky PE. Generation of nondividing high rate Ig-secreting plasma cells in cultures of human B cells stimulated with anti-CD3-activated T cells. J Immunol 1992; 148:404–410.PubMedGoogle Scholar
  9. 9.
    Gavarotti P, Boccadoro M, Redoglia V, Golzio F, Pileri A. Reactive plasmacytosis: case report and review of the literature. Acta Haematol 1985; 73:108–110.PubMedCrossRefGoogle Scholar
  10. 10.
    Jego G, Robillard N, Puthier D, et al. Reactive plasmacytoses are expansions of plasmablasts retaining the capacity to differentiate into plasma cells. Blood 1999; 94:701–712.PubMedGoogle Scholar
  11. 11.
    Tarte K, De Vos J, Thykjaer T, et al. Generation of polyclonal plasmablasts from peripheral blood B cells: a normal counterpart of malignant plasmablasts. Blood 2002; 100:1113–1122.PubMedGoogle Scholar
  12. 12.
    Jourdan M, Bataille R, Seguin J, Zhang XG, Chaptal PA, Klein B. Constitutive production of interleukin-6 and immunologic features in cardiac myxomas. Arthritis Rheum 1990; 33:398–402.PubMedCrossRefGoogle Scholar
  13. 13.
    MacMillan R, Longmire RL, Yelenosky R, Lang JE, Heath V, Craddock CG. Immunoglobulin synthesis by human lymphoid tissues : normal bone marrow as a major site of IgG production. J Immunol 1972; 109:1386–1390.Google Scholar
  14. 14.
    Hibi T, Dosch HM. Limiting dilution analysis of the B cell compartment in human bone marrow. Eur J Immunol 1986; 16:139–145.PubMedCrossRefGoogle Scholar
  15. 15.
    Manz RA, Radbruch A. Plasma cells for a lifetime? Eur J Immunol 2002; 32:923–927.PubMedCrossRefGoogle Scholar
  16. 16.
    Suematsu S, Matsuda T, Aozasa K, et al. IgG 1 plasmacytosis in interleukin 6 transgenic mice. Proceedings of the National Academy of Sciences of the United States of America 1989; 86:7547–7551.PubMedCrossRefGoogle Scholar
  17. 17.
    Muraguchi A, Hirano T, Tang B, et al. The essential role of B cell stimulatory factor 2 (BSF-2/ IL-6) for the terminal differentiation of B cells. J Exp Med 1988; 167:332–340.PubMedCrossRefGoogle Scholar
  18. 18.
    Roldan E, Brieva JA. Terminal differentiation of human bone marrow cells capable of spontaneous and high-rate immunoglobulin secretion: role of bone marrow stromal cells and interleukin 6. Eur J Immunol 1991; 21:2671–1677.PubMedCrossRefGoogle Scholar
  19. 19.
    Kawano MM, Mihara K, Huang N, Tsujimoto T, Kuramoto A. Differentiation of early plasma cells on bone marrow stromal cells requires interleukin-6 for escaping from apoptosis. Blood 1995; 85:487–494.PubMedGoogle Scholar
  20. 20.
    Brieva JA, Roldan E, Rodriguez C, Navas G. Human tonsil, blood and bone marrow in vivoinduced B cells capable of spontaneous and high-rate immunoglobulin secretion in vitro: differences in the requirements for factors and for adherent and bone marrow stromal cells, as well as distinctive adhesion molecule expression. Eur J Immunol 1994; 24:362–366.PubMedCrossRefGoogle Scholar
  21. 21.
    Merville P, Dechanet J, Desmouliere A, et al. Bcl-2+ tonsillar plasma cells are rescued from apoptosis by bone marrow fibroblasts. J Exp Med 1996; 183:227–236.PubMedCrossRefGoogle Scholar
  22. 22.
    Roldan E, Garcia-Pardo A, Brieva JA. VLA-4-fibronectin interaction is required for the terminal differentiation of human bone marrow cells capable of spontaneous and high rate immunoglobulin secretion. J Exp Med 1992; 175:1739–1747.PubMedCrossRefGoogle Scholar
  23. 23.
    Cassese G, Arce S, Hauser AE, et al. Plasma cell survival is mediated by synergistic effects of cytokines and adhesion-dependent signals. J Immunol 2003; 171:1684–1690.PubMedGoogle Scholar
  24. 24.
    Manz RA, Thiel A, Radbruch A. Lifetime of plasma cells in the bone marrow. Nature 1997; 388:133–134.PubMedCrossRefGoogle Scholar
  25. 25.
    Slifka MK, Antia R, Whitmire JK, Ahmed R. Humoral immunity due to long-lived plasma cells. Immunity 1998; 8:363–372.PubMedCrossRefGoogle Scholar
  26. 26.
    Slifka MK, Ahmed R. Long-lived plasma cells: a mechanism for maintaining persistent antibody production. Curr Opin Immunol 1998; 10:252–258.PubMedCrossRefGoogle Scholar
  27. 27.
    Heinrich PC, Behrmann I, Muller-Newen G, Schaper F, Graeve L. Interleukin-6-type cytokine signalling through the gp 130/Jak/STAT pathway. Biochem J 1998; 334:297–314.PubMedGoogle Scholar
  28. 28.
    Kawano M, Hirano T, Matsuda T, et al. Autocrine generation and essential requirement of BSF-2/IL-6 for human multiple myeloma. Nature 1988; 332:83–85.PubMedCrossRefGoogle Scholar
  29. 29.
    Klein B, Zhang XG, Jourdan M, et al. Paracrine rather than autocrine regulation of myelomacell growth and differentiation by interleukin-6. Blood 1989; 73:517–526.PubMedGoogle Scholar
  30. 30.
    Zhang XG, Gaillard JP, Robillard N, et al. Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in human multiple myeloma. Blood 1994; 83:3654–3663.PubMedGoogle Scholar
  31. 31.
    Ferlin-Bezombes M, Jourdan M, Liautard J, Brochier J, Rossi JF, Klein B. IFN-alpha is a survival factor for human myeloma cells and reduces dexamethasone-induced apoptosis. J Immunol 1998; 161:2692–2699.PubMedGoogle Scholar
  32. 32.
    Gu ZJ, De Vos J, Rebouissou C, et al. Agonist anti-gp 130 transducer monoclonal antibodies are human myeloma cell survival and growth factors. Leukemia 2000; 14:188–197.PubMedCrossRefGoogle Scholar
  33. 33.
    Bataille R, Jourdan M, Zhang XG, Klein B. Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias. J Clin Invest 1989; 84:2008–2011.PubMedCrossRefGoogle Scholar
  34. 34.
    Ludwig H, Nachbaur DM, Fritz E, Krainer M, Huber H. Interleukin-6 is a prognostic factor in multiple myeloma. Blood 1991; 77:2794–2795.PubMedGoogle Scholar
  35. 35.
    Klein B, Wijdenes J, Zhang XG, et al. Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia. Blood 1991; 78:1198–1204.PubMedGoogle Scholar
  36. 36.
    Bataille R, Boccadoro M, Klein B, Durie B, Pileri A. C-reactive protein and beta-2 microglobulin produce a simple and powerful myeloma staging system. Blood 1992; 80:733–737.PubMedGoogle Scholar
  37. 37.
    Klein B, Zhang XG, Lu ZY, Bataille R. Interleukin-6 in human multiple myeloma. Blood 1995; 85:863–872.PubMedGoogle Scholar
  38. 38.
    Uchiyama H, Barut BA, Mohrbacher AF, Chauhan D, Anderson KC. Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion. Blood 1993; 82:3712–3720.PubMedGoogle Scholar
  39. 39.
    Bloem AC, Lamme T, de Smet M, et al. Long-term bone marrow cultured stromal cells regulate myeloma tumour growth in vitro: studies with primary tumour cells and LTBMCdependent cell lines. Br J Haematology 1998; 100:166–175.CrossRefGoogle Scholar
  40. 40.
    Costes V, Portier M, Lu ZY, Rossi JF, Bataille R, Klein B. Interleukin-1 in multiple myeloma: producer cells and their role in the control of IL-6 production. Br J Haematol 1998; 103:1152–1160.PubMedCrossRefGoogle Scholar
  41. 41.
    Bataille R, Barlogie B, Lu ZY, et al. Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma. Blood 1995; 86:685–691.PubMedGoogle Scholar
  42. 42.
    Lu ZY, Brailly H, Wijdenes J, Bataille R, Rossi JF, Klein B. Measurement of whole body interleukin-6 (IL-6) production: prediction of the efficacy of anti-IL-6 treatments. Blood 1995; 86:3123–3131.PubMedGoogle Scholar
  43. 43.
    Klein B, Brailly H. Cytokine-binding proteins: stimulating antagonists. Immunol Today 1995; 16:216–220.PubMedCrossRefGoogle Scholar
  44. 44.
    Nordan RP, Potter M. A macrophage-derived factor required by plasmacytomas for survival and proliferation in vitro. Science 1986; 233:566–569.PubMedCrossRefGoogle Scholar
  45. 45.
    Simpson RJ, Moritz RL, Rubira MR, Van Snick J. Murine hybridoma/plasmacytoma growth factor: complete amino-acid sequence and relation to human interleukin-6. Eur J Biochem 1988; 176:187–197.PubMedCrossRefGoogle Scholar
  46. 46.
    Lattanzio G, Libert C, Aquilina M, et al. Defective development of pristane-oil-induced plasmacytomas in interleukin-6-deficient BALB/c mice. Am J Pathol 1997; 151:689–696.PubMedGoogle Scholar
  47. 47.
    Suematsu S, Matsusaka T, Matsuda T, et al. Generation of plasmacytomas with the chromosomal translocation t(12;15) in interleukin 6 transgenic mice. Proceedings of the National Academy of Sciences of the United States of America 1992; 89:232–235.PubMedCrossRefGoogle Scholar
  48. 48.
    Hilbert DM, Kopf M, Mock BA, Kohler G, Rudikoff S. Interleukin 6 is essential for in vivo development of B lineage neoplasms. J Exp Med 1995; 182:243–248.PubMedCrossRefGoogle Scholar
  49. 49.
    Gu ZJ, Zhang XG, Hallet MM, et al. A ciliary neurotrophic factor-sensitive human myeloma cell line. Exp Hematol 1996; 24:1195–1200.PubMedGoogle Scholar
  50. 50.
    Gu ZJ, Costes V, Lu ZY, et al. Interleukin-10 is a growth factor for human myeloma cells by induction of an oncostatin M autocrine loop. Blood 1996; 88:3972–3986.PubMedGoogle Scholar
  51. 51.
    Rettig MB, Ma HJ, Vescio RA, et al. Kaposi’s sarcoma-associated herpesvirus infection of bone marrow dendritic cells from multiple myeloma patients. Science 1997; 276:1851–1854.PubMedCrossRefGoogle Scholar
  52. 52.
    Burger R, Neipel F, Fleckenstein B, et al. Human herpesvirus type 8 interleukin-6 homologue is functionally active on human myeloma cells. Blood 1998; 91:1858–1863.PubMedGoogle Scholar
  53. 52a.
    Tarte K, Olsen SJ, Lu ZY, et al. Clinical-grade functional dendritic cells from patients with multiple myeloma are not infected with Kaposi’s sarcoma-associated herpesvirus. Blood 1998; 91:1852–1857.PubMedGoogle Scholar
  54. 53.
    Tarte K, Chang Y, Klein B. Kaposi’s sarcoma-associated herpesvirus and multiple myeloma: lack of criteria for causality. Blood 1999; 93:3159–3163.PubMedGoogle Scholar
  55. 54.
    Lu ZY, Zhang XG, Rodriguez C, et al. Interleukin-10 is a proliferation factor but not a differentiation factor for human myeloma cells. Blood 1995; 85:2521–2527.PubMedGoogle Scholar
  56. 55.
    Lu ZY, Gu ZJ, Zhang XG, et al. Interleukin-10 induces interleukin-11 responsiveness in human myeloma cell lines. FEBS Lett 1995; 377:515–518.PubMedCrossRefGoogle Scholar
  57. 56.
    Tosato G, Jones KD. Interleukin-1 induces interleukin-6 production in peripheral blood monocytes. Blood 1990; 75:1305–1310.PubMedGoogle Scholar
  58. 57.
    Dinarello CA. Biologic basis for interleukin-1 in disease. Blood 1996; 87:2095–2147.PubMedGoogle Scholar
  59. 58.
    Kawano M, Tanaka H, Ishikawa H, et al. Interleukin-1 accelerates autocrine growth of myeloma cells through interleukin-6 in human myeloma. Blood 1989; 73:2145–2148.PubMedGoogle Scholar
  60. 59.
    Cozzolino F, Torcia M, Aldinucci D, et al. Production of interleukin-1 by bone marrow myeloma cells. Blood 1989; 74:380–387.PubMedGoogle Scholar
  61. 60.
    Carter A, Merchav S, Silvian-Draxler I, Tatarsky I. The role of interleukin-1 and tumour necrosis factor-alpha in human multiple myeloma. Br J Haematol 1990; 74:424–431.PubMedCrossRefGoogle Scholar
  62. 61.
    Borset M, Helseth E, Naume B, Waage A. Lack of IL-1 secretion from human myeloma cells highly purified by immunomagnetic separation. Br. J Haematol 1993; 85:446–451.PubMedCrossRefGoogle Scholar
  63. 62.
    Hinson RM, Williams JA, Shacter E. Elevated interleukin 6 is induced by prostaglandin E2 in a murine model of inflammation: possible role of cyclooxygenase-2. Proc Natl Acad Sci U S A 1996; 93:4885–4890.PubMedCrossRefGoogle Scholar
  64. 63.
    Kawano M, Yamamoto I, Iwato K, et al. Interleukin-1 beta rather than lymphotoxin as the major bone resorbing activity in human multiple myeloma. Blood 1989; 73:1646–1649.PubMedGoogle Scholar
  65. 64.
    Torcia M, Lucibello M, Vannier E, et al. Modulation of osteoclast-activating factor activity of multiple myeloma bone marrow cells by different interleukin-1 inhibitors. Exp Hematol 1996; 24:868–874.PubMedGoogle Scholar
  66. 65.
    Tinhofer I, Marschitz I, Henn T, Egle A, Greil R. Expression of functional interleukin-15 receptor and autocrine production of interleukin-15 as mechanisms of tumor propagation in multiple myeloma. Blood 2000; 95:610–618.PubMedGoogle Scholar
  67. 66.
    Hjorth-Hansen H, Waage A, Borset M. Interleukin-15 blocks apoptosis and induces proliferation of the human myeloma cell line OH-2 and freshly isolated myeloma cells. Br J Haematol 1999; 106:28–34.PubMedCrossRefGoogle Scholar
  68. 67.
    Till KJ, Burthem J, Lopez A, Cawley JC. Granulocyte-macrophage colony-stimulating factor receptor: stage-specific expression and function on late B cells. Blood 1996; 88:479–486.PubMedGoogle Scholar
  69. 68.
    Villunger A, Egle A, Kos M, et al. Functional granulocyte/macrophage colony stimulating factor receptor is constitutively expressed on neoplastic plasma cells and mediates tumour cell longevity. Br J Haematol 1998; 102:1069–1080.PubMedCrossRefGoogle Scholar
  70. 69.
    Zhang XG, Bataille R, Jourdan M, et al. Granulocyte-macrophage colony-stimulating factor synergizes with interleukin-6 in supporting the proliferation of human myeloma cells. Blood 1990; 76:2599–2605.PubMedGoogle Scholar
  71. 70.
    Portier M, Zhang XG, Ursule E, et al. Cytokine gene expression in human multiple myeloma. Br J Haematol 1993; 85:514–520.PubMedCrossRefGoogle Scholar
  72. 71.
    Nachbaur D, Herold M, Huber H. Endogenous circulating granulocyte-macrophage colonystimulating factor in multiple myeloma. Blood 1991; 78:539–540.PubMedGoogle Scholar
  73. 72.
    Peest D, Blade J, Harousseau JL, Klein B, Osterborg A, San Miguel JF. Cytokine therapy in multiple myeloma. Br. J Haematol 1996; 94:425–432.PubMedCrossRefGoogle Scholar
  74. 73.
    Brenning G. The in vitro effect of leucocyte alpha-interferon on human myeloma cells in a semisolid agar culture system. Scand J Haematol 1985; 35:178–185.PubMedCrossRefGoogle Scholar
  75. 74.
    Palumbo A, Battaglio S, Napoli P, et al. Recombinant interferon-gamma inhibits the in vitro proliferation of human myeloma cells. Br J Haematol 1994; 86:726–732.PubMedCrossRefGoogle Scholar
  76. 75.
    Jelinek DF, Aagaard-Tillery KM, Arendt BK, Arora T, Tschumper RC, Westendorf JJ. Differential human multiple myeloma cell line responsiveness to interferon-alpha: analysis of transcription factor activation and interleukin 6 receptor expression. J Clin Invest 1997; 99:447–456.PubMedCrossRefGoogle Scholar
  77. 76.
    Jourdan M, Zhang XG, Portier M, Boiron JM, Bataille R, Klein B. IFN-alpha induces autocrine production of IL-6 in myeloma cell lines. J Immunol 1991; 147:4402–4407.PubMedGoogle Scholar
  78. 77.
    French JD, Walters DK, Jelinek DF. Transactivation of gp130 in myeloma cells. J Immunol 2003; 170:3717–3723.PubMedGoogle Scholar
  79. 78.
    Berger LC, Hawley RG. Interferon-beta interrupts interleukin-6-dependent signaling events in myeloma cells. Blood 1997; 89:261–271.PubMedGoogle Scholar
  80. 79.
    Arora T, Jelinek DF. Differential myeloma cell responsiveness to interferon-alpha correlates with differential induction of p19(INK4d) and cyclin D2 expression. J Biol Chem 1998; 273:11799–11805.PubMedCrossRefGoogle Scholar
  81. 80.
    Liu P, Oken M, Van Ness B. Interferon-alpha protects myeloma cell lines from dexamethasone-induced apoptosis. Leukemia 1999; 13:473–480.PubMedCrossRefGoogle Scholar
  82. 81.
    Egle A, Villunger A, Kos M, et al. Modulation of Apo-1/Fas (CD95)-induced programmed cell death in myeloma cells by interferon-alpha 2. Eur J Immunol 1996; 26:3119–3126.PubMedCrossRefGoogle Scholar
  83. 82.
    Spets H, Georgii-Hemming P, Siljason J, Nilsson K, Jernberg-Wiklund H. Fas/APO-1 (CD95)-mediated apoptosis is activated by interferon-gamma and interferon- in interleukin-6 (IL-6)-dependent and IL-6-independent multiple myeloma cell lines. Blood 1998; 92:2914–2923.PubMedGoogle Scholar
  84. 83.
    Gutterman JU. Cytokine therapeutics: lessons from interferon alpha. Proc Natl Acad Sci U S A 1994; 91:1198–1205.PubMedCrossRefGoogle Scholar
  85. 84.
    Blade J, Lopez-Guillermo A, Tassies D, Montserrat E, Rozman C. Development of aggressive plasma cell leukaemia under interferon-alpha therapy. Br J Haematol 1991; 79:523–525.PubMedCrossRefGoogle Scholar
  86. 85.
    Sawamura M, Murayama K, Ui G, et al. Plasma cell leukaemia with alpha-interferon therapy in myeloma. Br J Haematol 1992; 82:631.PubMedCrossRefGoogle Scholar
  87. 86.
    Tanaka H, Tanabe O, Iwato K, et al. Sensitive inhibitory effect of interferon-alpha on M-protein secretion of human myeloma cells. Blood 1989; 74:1718–1722.PubMedGoogle Scholar
  88. 87.
    Portier M, Zhang XG, Caron E, Lu ZY, Bataille R, Klein B. gamma-Interferon in multiple myeloma: inhibition of interleukin-6 (IL-6)-dependent myeloma cell growth and downregulation of IL-6-receptor expression in vitro. Blood 1993; 81:3076–3082.PubMedGoogle Scholar
  89. 88.
    Ossina NK, Cannas A, Powers VC, et al. Interferon-gamma modulates a p53-independent apoptotic pathway and apoptosis-related gene expression. J Biol Chem 1997; 272: 16351–16357.PubMedCrossRefGoogle Scholar
  90. 89.
    Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. Science 1998; 281:1305–1308.PubMedCrossRefGoogle Scholar
  91. 90.
    Van Antwerp DJ, Martin SJ, Kafri T, Green DR, Verma IM. Suppression of TNF-alphainduced apoptosis by NF-kappaB. Science 1996; 274:787–789.PubMedCrossRefGoogle Scholar
  92. 91.
    Lee SY, Reichlin A, Santana A, Sokol KA, Nussenzweig MC, Choi Y. TRAF2 is essential for JNK but not NF-kappaB activation and regulates lymphocyte proliferation and survival. Immunity 1997; 7:703–713.PubMedCrossRefGoogle Scholar
  93. 92.
    Borset M, Waage A, Brekke OL, Helseth E. TNF and IL-6 are potent growth factors for OH-2, a novel human myeloma cell line. Eur J Haematol 1994; 53:31–37.PubMedCrossRefGoogle Scholar
  94. 93.
    Jourdan M, Tarte K, Legouffe E, Brochier J, Rossi JF, Klein B. Tumor necrosis factor is a survival and proliferation factor for human myeloma cells. Eur Cytokine Netw 1999; 10:65–70.PubMedGoogle Scholar
  95. 94.
    Hideshima T, Chauhan D, Schlossman R, Richardson P, Anderson KC. The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications. Oncogene 2001; 20:4519–4527.PubMedCrossRefGoogle Scholar
  96. 95.
    Lichtenstein A, Berenson J, Norman D, Chang MP, Carlile A. Production of cytokines by bone marrow cells obtained from patients with multiple myeloma. Blood 1989; 74:1266–1273.PubMedGoogle Scholar
  97. 96.
    Filella X, Blade J, Guillermo AL, Molina R, Rozman C, Ballesta AM. Cytokines (IL-6, TNF-alpha, IL-1 alpha) and soluble interleukin-2 receptor as serum tumor markers in multiple myeloma. Cancer Detect Prey 1996; 20:52–56.Google Scholar
  98. 97.
    Blade J, Filella X, Montoto S, et al. Clinical relevance of interleukin 6 and tumor necrosis factor alpha serum levels in monoclonal gammopathy of undetermined significance [abstract]. Blood 1997; 90:351a.Google Scholar
  99. 98.
    Baserga R. The insulin-like growth factor I receptor: a key to tumor growth? Cancer Res 1995; 55:249–252.PubMedGoogle Scholar
  100. 99.
    Christofori G, Naik P, Hanahan D. A second signal supplied by insulin-like growth factor II in oncogene-induced tumorigenesis. Nature 1994; 369:414–418.PubMedCrossRefGoogle Scholar
  101. 100.
    Chan JM, Stampfer MJ, Giovannucci E, et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 1998; 279:563–566.PubMedCrossRefGoogle Scholar
  102. 101.
    Georgii-Hemming P, Wiklund HJ, Ljunggren O, Nilsson K. Insulin-like growth factor I is a growth and survival factor in human multiple myeloma cell lines. Blood 1996; 88:2250–2258.PubMedGoogle Scholar
  103. 102.
    Nishiura T, Karasuno T, Yoshida H, et al. Functional role of cation-independent mannose 6-phosphate/insulin-like growth factor II receptor in cell adhesion and proliferation of a human myeloma cell line OPM-2. Blood 1996; 88:3546–3554.PubMedGoogle Scholar
  104. 103.
    Jelinek DF, Witzig TE, Arendt BK. A role for insulin-like growth factor in the regulation of IL-6-responsive human myeloma cell line growth. J Immunol 1997; 159:487–496.PubMedGoogle Scholar
  105. 104.
    Ferlin M, Noraz N, Hertogh C, Brochier J, Taylor N, Klein B. Insulin-like growth factor induces the survival and proliferation of myeloma cells through an IL-6-independent transduction pathway. Br J Haematol 2000; 111:626–634.PubMedCrossRefGoogle Scholar
  106. 105.
    Ge NL, Rudikoff S. Insulin-like growth factor I is a dual effector of multiple myeloma cell growth. Blood 2000; 96:2856–2861.PubMedGoogle Scholar
  107. 106.
    Li W, Hyun T, Heller M, et al. Activation of insulin-like growth factor I receptor signaling pathway is critical for mouse plasma cell tumor growth. Cancer Res 2000; 60:3909–3915.PubMedGoogle Scholar
  108. 107.
    Arai T, Parker A, Busby W, Jr., Clemmons DR. Heparin, heparan sulfate, and dermatan sulfate regulate formation of the insulin-like growth factor-I and insulin-like growth factorbindingprotein complexes. J Biol Chem 1994; 269:20388–20393.PubMedGoogle Scholar
  109. 108.
    Chesi M, Nardini E, Brents LA, et al. Frequent translocation t(4;14)(p 16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nature Genetics 1997; 16:260–264.PubMedCrossRefGoogle Scholar
  110. 109.
    Onwuazor ON, Wen XY, Wang DY, et al. Mutation, SNP, and isoform analysis of fibroblast growth factor receptor 3 (FGFR3) in 150 newly diagnosed multiple myeloma patients. Blood 2003; 102:772–773.PubMedCrossRefGoogle Scholar
  111. 110.
    Fracchiolla NS, Luminari S, Baldini L, Lombardi L, Maiolo AT, Neri A. FGFR3 gene mutations associated with human skeletal disorders occur rarely in multiple myeloma. Blood 1998; 92:2987–2989.PubMedGoogle Scholar
  112. 111.
    Kan M, Wang F, Xu J, Crabb JW, Hou J, McKeehan WL. An essential heparin-binding domain in the fibroblast growth factor receptor kinase. Science 1993; 259:1918–1921.PubMedCrossRefGoogle Scholar
  113. 112.
    Ridley RC, Xiao H, Hata H, Woodliff J, Epstein J, Sanderson RD. Expression of syndecan regulates human myeloma plasma cell adhesion to type I collagen. 1993; 81:767–774.Google Scholar
  114. 113.
    Jourdan M, Ferlin M, Legouffe E, et al. The myeloma cell antigen syndecan-1 is lost by apoptotic mveloma cells. Br J Haematol 1998: 100:637–646.PubMedCrossRefGoogle Scholar
  115. 114.
    Witzig TE, Kimlinger T, Stenson M, Therneau T. Syndecan-1 expression on malignant cells from the blood and marrow of patients with plasma cell proliferative disorders and B-cell chronic lymphocytic leukemia. Leuk Lymphoma 1998; 31:167–175.PubMedCrossRefGoogle Scholar
  116. 115.
    Subramanian SV, Fitzgerald ML, Bernfield M. Regulated shedding of syndecan-1 and -4 ectodomains by thrombin and growth factor receptor activation. J Biol Chem 1997; 272:14713–14720.PubMedCrossRefGoogle Scholar
  117. 116.
    Dhodapkar MV, Kelly T, Theus A, Athota AB, Barlogie B, Sanderson RD. Elevated levels of shed syndecan-1 correlate with tumour mass and decreased matrix metalloproteinase-9 activity in the serum of patients with multiple myeloma [published erratum appears in Br J Haematol 1998 May;101(2):398]. Br J Haematol 1997; 99:368–371.Google Scholar
  118. 117.
    Klein B, Li XY, Lu ZY, et al. Activation molecules on human myeloma cells. Curr Topics Microbiol Immunol 1999. In press.Google Scholar
  119. 118.
    Yang Y, Yaccoby S, Liu W, et al. Soluble syndecan-1 promotes growth of myeloma tumors in vivo. Blood 2002; 100:610–617.PubMedCrossRefGoogle Scholar
  120. 119.
    Kato M, Wang H, Kainulainen V, et al. Physiological degradation converts the soluble syndecan1 ectodomain from an inhibitor to a potent activator of FGF-2. Nat Med 1998; 4:691–697.PubMedCrossRefGoogle Scholar
  121. 120.
    Bisping G, Leo R, Wenning D, et al. Paracrine interactions of basic fibroblast growth factor and interleukin-6 in multiple myeloma. Blood 2003; 101:2775–2783.PubMedCrossRefGoogle Scholar
  122. 121.
    Vacca A, Ribatti D, Presta M, et al. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood 1999; 93:3064–3073.PubMedGoogle Scholar
  123. 122.
    Zarnegar R, Michalopoulos GK. The many faces of hepatocyte growth factor: from hepatopoiesis to hematopoiesis. J Cell Biol 1995; 129:1177–1180.PubMedCrossRefGoogle Scholar
  124. 123.
    Borset M, Hjorth-Hansen H, Seidel C, Sundan A, Waage A. Hepatocyte growth factor and its receptor c-met in multiple mveloma. Blood 1996: 88:3998–4004.PubMedGoogle Scholar
  125. 124.
    Seidel C, Borset M, Turesson I, Abildgaard N, Sundan A, Waage AElevated serum concentrations of hepatocyte growth factor in patients with multiple myeloma. The Nordic Myeloma Study Group. Blood 1998; 91:806–812.PubMedGoogle Scholar
  126. 125.
    Grano M, Galimi F, Zambonin G, et al. Hepatocyte growth factor is a coupling factor for osteoclasts and osteoblasts in vitro. Proc Natl Acad Sci U S A 1996; 93:7644–7648.PubMedCrossRefGoogle Scholar
  127. 126.
    Hjertner O, Torgersen ML, Seidel C, et al. Hepatocyte growth factor (HGF) induces interleukin-11 secretion from osteoblasts: a possible role for HGF in myeloma-associated osteolytic bone disease. Blood 1999; 94:3883–3888.PubMedGoogle Scholar
  128. 127.
    De Vos J, Couderc G, Tarte K, et al. Identifying intercellular signaling genes expressed in malignant plasma cells by using complementary DNA arrays. Blood 2001; 98:771–780.PubMedCrossRefGoogle Scholar
  129. 128.
    Wang YD, De Vos J, Jourdan M, et al. Cooperation between heparin-binding EGF-like growth factor and interleukin-6 in promoting the growth of human myeloma cells. Oncogene 2002; 21:2584–2592.PubMedCrossRefGoogle Scholar
  130. 129.
    Davis-Fleischer KM, Besner GE. Structure and function of heparin-binding EGF-like growth factor (HB-EGF). Frontiers in Bioscience 1998; 3:d288-d299.Google Scholar
  131. 130.
    Vacca A, Ribatti D, Roncali L, et al. Bone marrow angiogenesis and progression in multiple myeloma. Br. J Haematol 1994; 87:503–508.PubMedCrossRefGoogle Scholar
  132. 131.
    Dankbar B, Padro T, Leo R, et al. Vascular endothelial growth factor and interleukin6 in paracrine tumor-stromal cell interactions in multiple myeloma. Blood 2000; 95:2630–2636.PubMedGoogle Scholar
  133. 132.
    Bellamy WT, Richter L, Frutiger Y, Grogan TM. Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. Cancer Res 1999; 59:728–733.PubMedGoogle Scholar
  134. 133.
    Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341:1565–1571.PubMedCrossRefGoogle Scholar
  135. 134.
    Pearse RN, Sordillo EM, Yaccoby S, et al. Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc Natl Acad Sci U S A 2001; 98:11581–11586.PubMedCrossRefGoogle Scholar
  136. 135.
    Giuliani N, Bataille R, Mancini C, Lazzaretti M, Barille S. Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment. Blood 2001; 98:3527–3533.PubMedCrossRefGoogle Scholar
  137. 136.
    Croucher PI, Shipman CM, Lippitt J, et al. Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. Blood 2001; 98:3534–3540.PubMedCrossRefGoogle Scholar
  138. 137.
    Abe M, Hiura K, Wilde J, et al. Role for macrophage inflammatory protein (MIP)- l alpha and MIP-1 beta in the development of osteolytic lesions in multiple myeloma. Blood 2002; 100:2195–2202.PubMedGoogle Scholar
  139. 138.
    Mackay F, Kalled SL. TNF ligands and receptors in autoimmunity: an update. Curr Opin Immunol 2002; 14:783–790.PubMedCrossRefGoogle Scholar
  140. 139.
    Claudio JO, Masih-Khan E, Tang H, et al. A molecular compendium of genes expressed in multiple myeloma. Blood 2002; 100:2175–2186.PubMedCrossRefGoogle Scholar
  141. 140.
    Tarte K, Moreaux J, Legouffe E, Rossi JF, Klein B. BAFF Is a survival factor for multiple myeloma cells [abstract]. Blood 2002; Abstract 3 203.Google Scholar
  142. 141.
    Sitnicka E, Ruscetti FW, Priestley GV, Wolf NS, Bartelmez SH. Transforming growth factor beta 1 directly and reversibly inhibits the initial cell divisions of long-term repopulating hematopoietic stem cells. Blood 1996; 88:82–88.PubMedGoogle Scholar
  143. 142.
    Jansen R, Damia G, Usui N, et al. Effects of recombinant transforming growth factor-beta 1 on hematologic recovery after treatment of mice with 5-fluorouracil. J Immunol 1991; 147:3342–3347.PubMedGoogle Scholar
  144. 143.
    Matthes T, Werner-Favre C, Zubler RH. Cytokine expression and regulation of human plasma cells: disappearance of interleukin-10 and persistence of transforming growth factorbeta 1. Eur J Immunol 1995: 25:508–512.PubMedCrossRefGoogle Scholar
  145. 144.
    Amoroso SR, Huang N, Roberts AB, Potter M, Letterio JJ. Consistent loss of functional transforming growth factor beta receptor expression in murine plasmacytomas. Proc Natl Acad Sci U S A 1998; 95:189–194.PubMedCrossRefGoogle Scholar
  146. 145.
    Berg DJ, Lynch RG. Immune dysfunction in mice with plasmacytomas. I. Evidence that transforming growth factor-beta contributes to the altered expression of activation receptors on host B lymphocytes. J Immunol 1991; 146:2865–2872.PubMedGoogle Scholar
  147. 146.
    Urashima M, Ogata A, Chauhan D, et al. Transforming growth factor-beta l : differential effects on multiple myeloma versus normal B cells. Blood 1996; 87:1928–1938.PubMedGoogle Scholar
  148. 147.
    Tsujimoto T, Lisukov IA, Huang N, Mahmoud MS, Kawano MM. Plasma cells induce apoptosis of pre-B cells by interacting with bone marrow stromal cells. Blood 1996; 87: 3375–3383.PubMedGoogle Scholar
  149. 148.
    Kyrtsonis MC, Repa C, Dedoussis GV, et al. Serum transforming growth factor-beta 1 is related to the degree of immunoparesis in patients with multiple myeloma. Med Oncol 1998; 15:124–128.PubMedCrossRefGoogle Scholar
  150. 149.
    Lemoli RM, Fortuna A, Grande A, et al. Expression and functional role of c-kit ligand (SCF) in human multiple myeloma cells. 1994; 88:760–769.Google Scholar
  151. 150.
    Bergui L, Schena M, Gaidano G, Riva M, Caligaris C. Interleukin 3 and interleukin 6 synergistically promote the proliferation and differentiation of malignant plasma cell precursors in multiple myeloma. 1989; 170:613–618.Google Scholar
  152. 151.
    Okuno Y, Takahashi T, Suzuki A, et al. Establishment and characterization of four myeloma cell lines which are responsive to interleukin-6 for their growth. Leukemia 1991; 5:585–591.PubMedGoogle Scholar
  153. 152.
    Anderson KC, Jones RM, Morimoto C, Leavitt P, Barut BA. Response patterns of purified myeloma cells to hematopoietic growth factors. Blood 1989; 73:1915–1924.PubMedGoogle Scholar
  154. 153.
    Hallek M, Leif BP, Anderson KC. Multiple myeloma: increasing evidence for a multistep transformation process. Blood 1998; 91:3–21.PubMedGoogle Scholar
  155. 154.
    Van Riet I, De Greef C, Aharchi F, et al. Establishment and characterization of a human stroma-dependent myeloma cell line (MM5.1) and its stroma-independent variant (MM5.2). Leukemia 1997; 11:284–293.PubMedCrossRefGoogle Scholar
  156. 155.
    Degrassi A, Hibert DM, Rudikoff S, Anderson AO, Potter M, Coon HG. In vitro culture of primary plasmacytomas requires stromal cell feeder layers. Proc Nat Acad Sci U S A 1993; 90:2060–2064.CrossRefGoogle Scholar
  157. 156.
    Podar K, Tai YT, Cole CE, et al. Essential role of caveolae in interleukin-6- and insulin-like growth factor I-triggered Akt-1-mediated survival of multiple myeloma cells. J Biol Chem 2003; 278:5794–5801.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2004

Authors and Affiliations

  • John De Vos
  • Bernard Klein

There are no affiliations available

Personalised recommendations